These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 24841172

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
    Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN.
    Bioconjug Chem; 2005; 16(1):200-7. PubMed ID: 15656592
    [Abstract] [Full Text] [Related]

  • 3. Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b.
    Lee JI, Eisenberg SP, Rosendahl MS, Chlipala EA, Brown JD, Doherty DH, Cox GN.
    J Interferon Cytokine Res; 2013 Dec; 33(12):769-77. PubMed ID: 23962003
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor.
    Doherty DH, Rosendahl MS, Smith DJ, Hughes JM, Chlipala EA, Cox GN.
    Bioconjug Chem; 2005 Dec; 16(5):1291-8. PubMed ID: 16173810
    [Abstract] [Full Text] [Related]

  • 6. Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity.
    Long DL, Doherty DH, Eisenberg SP, Smith DJ, Rosendahl MS, Christensen KR, Edwards DP, Chlipala EA, Cox GN.
    Exp Hematol; 2006 Jun; 34(6):697-704. PubMed ID: 16728273
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW, Youn YS, Lee SH, Kim BM, Kang SH, Yoo M, Choi EC, Lee KC.
    Int J Pharm; 2006 Feb 17; 309(1-2):87-93. PubMed ID: 16406701
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Novel pegylated interferon-β as strong suppressor of the malignant ascites in a peritoneal metastasis model of human cancer.
    Iwamura T, Narumi H, Suzuki T, Yanai H, Mori K, Yamashita K, Tsushima Y, Asano T, Izawa A, Momen S, Nishimura K, Tsuchiyama H, Uchida M, Yamashita Y, Okano K, Taniguchi T.
    Cancer Sci; 2017 Apr 17; 108(4):581-589. PubMed ID: 28129467
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.